Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents

Keizo Yamaguchi, Nobuhiko Furuya, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Mitsuo Kaku, Yuko Abe, Jun Igari, Toyoko Oguri, Hisashi Baba, Hitoshi Yoshimura, Kiyoharu Yamanaka, Satoshi Ischiyama, Nobuchika Kusano, Naoko Murao, Junko Ono, Hiromi Tou, Kaoru Okada & 3 others Masami Ishida, Yoichi Hirakata, Junichi Matsuda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5%. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67%. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.

Original languageEnglish
Pages (from-to)627-640
Number of pages14
JournalJapanese Journal of Chemotherapy
Volume53
Issue number10
Publication statusPublished - Oct 2005

Fingerprint

Anti-Infective Agents
Fluoroquinolones
Streptococcus pneumoniae
Moraxella (Branhamella) catarrhalis
Enterococcus faecalis
Haemophilus influenzae
Escherichia coli
Penicillin Resistance
Otolaryngology
gatifloxacin
Sputum
Urinary Tract Infections
Respiratory System
Japan
Urine
Drug Therapy

Keywords

  • Fluoroquinolone
  • Gatifloxacin
  • Surveillance

ASJC Scopus subject areas

  • Pharmacology

Cite this

Yamaguchi, K., Furuya, N., Iwata, M., Watanabe, N., Uehara, N., Yasujima, M., ... Matsuda, J. (2005). Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. Japanese Journal of Chemotherapy, 53(10), 627-640.

Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. / Yamaguchi, Keizo; Furuya, Nobuhiko; Iwata, Morihiro; Watanabe, Naoki; Uehara, Nobuyuki; Yasujima, Minoru; Kasai, Takeshi; Kaku, Mitsuo; Abe, Yuko; Igari, Jun; Oguri, Toyoko; Baba, Hisashi; Yoshimura, Hitoshi; Yamanaka, Kiyoharu; Ischiyama, Satoshi; Kusano, Nobuchika; Murao, Naoko; Ono, Junko; Tou, Hiromi; Okada, Kaoru; Ishida, Masami; Hirakata, Yoichi; Matsuda, Junichi.

In: Japanese Journal of Chemotherapy, Vol. 53, No. 10, 10.2005, p. 627-640.

Research output: Contribution to journalArticle

Yamaguchi, K, Furuya, N, Iwata, M, Watanabe, N, Uehara, N, Yasujima, M, Kasai, T, Kaku, M, Abe, Y, Igari, J, Oguri, T, Baba, H, Yoshimura, H, Yamanaka, K, Ischiyama, S, Kusano, N, Murao, N, Ono, J, Tou, H, Okada, K, Ishida, M, Hirakata, Y & Matsuda, J 2005, 'Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents', Japanese Journal of Chemotherapy, vol. 53, no. 10, pp. 627-640.
Yamaguchi K, Furuya N, Iwata M, Watanabe N, Uehara N, Yasujima M et al. Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. Japanese Journal of Chemotherapy. 2005 Oct;53(10):627-640.
Yamaguchi, Keizo ; Furuya, Nobuhiko ; Iwata, Morihiro ; Watanabe, Naoki ; Uehara, Nobuyuki ; Yasujima, Minoru ; Kasai, Takeshi ; Kaku, Mitsuo ; Abe, Yuko ; Igari, Jun ; Oguri, Toyoko ; Baba, Hisashi ; Yoshimura, Hitoshi ; Yamanaka, Kiyoharu ; Ischiyama, Satoshi ; Kusano, Nobuchika ; Murao, Naoko ; Ono, Junko ; Tou, Hiromi ; Okada, Kaoru ; Ishida, Masami ; Hirakata, Yoichi ; Matsuda, Junichi. / Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents. In: Japanese Journal of Chemotherapy. 2005 ; Vol. 53, No. 10. pp. 627-640.
@article{9d60ba79f33248509845df3b6b4ebe47,
title = "Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents",
abstract = "In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5{\%}. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67{\%}. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.",
keywords = "Fluoroquinolone, Gatifloxacin, Surveillance",
author = "Keizo Yamaguchi and Nobuhiko Furuya and Morihiro Iwata and Naoki Watanabe and Nobuyuki Uehara and Minoru Yasujima and Takeshi Kasai and Mitsuo Kaku and Yuko Abe and Jun Igari and Toyoko Oguri and Hisashi Baba and Hitoshi Yoshimura and Kiyoharu Yamanaka and Satoshi Ischiyama and Nobuchika Kusano and Naoko Murao and Junko Ono and Hiromi Tou and Kaoru Okada and Masami Ishida and Yoichi Hirakata and Junichi Matsuda",
year = "2005",
month = "10",
language = "English",
volume = "53",
pages = "627--640",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "10",

}

TY - JOUR

T1 - Surveillance of susceptibility of clinical isolates to gatifloxacin and various antimicrobial agents

AU - Yamaguchi, Keizo

AU - Furuya, Nobuhiko

AU - Iwata, Morihiro

AU - Watanabe, Naoki

AU - Uehara, Nobuyuki

AU - Yasujima, Minoru

AU - Kasai, Takeshi

AU - Kaku, Mitsuo

AU - Abe, Yuko

AU - Igari, Jun

AU - Oguri, Toyoko

AU - Baba, Hisashi

AU - Yoshimura, Hitoshi

AU - Yamanaka, Kiyoharu

AU - Ischiyama, Satoshi

AU - Kusano, Nobuchika

AU - Murao, Naoko

AU - Ono, Junko

AU - Tou, Hiromi

AU - Okada, Kaoru

AU - Ishida, Masami

AU - Hirakata, Yoichi

AU - Matsuda, Junichi

PY - 2005/10

Y1 - 2005/10

N2 - In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5%. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67%. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.

AB - In order to continually examine the susceptibility of clinical isolates against gatifloxacin (GFLX), we conducted a surveillance measuring that of 2,508 strains of four gram-positive and seven gram-negative pathogens to 12 antimicrobials including GFLX, during the period from November 2004 to March 2005 following previous surveillance conducted in 2002. Tested pathogens were isolated from sputum, urine and sinus discharge obtained from 15 facilities throughout Japan. GFLX exhibited superior antibacterial activity against Streptococcus pneumoniae, comparison to other fluoroquinolones, by showing same MIG50 and MIC90 values of 0.25 μg/mL and a satisfactory susceptible rate at 96.5%. Antibacterial activity of GFLX was not influenced by the development of penicillin-resistance in S. pneumoniae. The MIC90 values of fluoroquinolones against Haemophilus influenzae and Moraxella catarrhalis were commonly as low as 0.015 μg/mL to 0.03 μg/mL. The MIC50 and MIC90 values of GFLX against Escherichia coli and Enterococcus faecalis were 0.06 μg/mL-0.5,4 μg/mL and 8 μg/mL-16 μg/mL, respectively. The susceptible rate for fluoroquinolones were 83-67%. On an average, this surveillance indicated that fluoroquinolones kept strong antibacterial activities against H. influenzae and M. catarrhalis. Among others, GFLX has maintained strong antibacterial activity against S. pneumoniae as the MIC90 value of 0.25 μg/mL was identical to that observed at the launch. It was thought that GFLX was the clinically useful drugs for empiric therapy against main pathogens of respiratory tract, otorhinolaryngology and urinary tract infections. While antibacterial activities of fluoroquinolones against E. coli and E. faecalis did not almost change from 2002 surveillance, it was thought the susceptibility needed to be examined continually in future.

KW - Fluoroquinolone

KW - Gatifloxacin

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=28444471310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444471310&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 627

EP - 640

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 10

ER -